Compass Therapeutics (CMPX) vs NervGen Pharma (NGEN)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
NervGen Pharma (NGEN) has outperformed Compass Therapeutics (CMPX) over the past year, losing 44.1% versus a loss of 71.7%. Over five years, NGEN leads with a -7.9% price change compared with -68.2% for CMPX. NervGen Pharma is the larger company by market cap ($184.9 million vs $180.8 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | CMPX | NGEN |
|---|---|---|
| Share price | $1.00 | $1.72 |
| Market cap | $180.81M | $184.94M |
| 1-day change | -1.57% | -1.14% |
| YTD return | -81.01% | -68.93% |
| 1-year return | -71.75% | -44.12% |
| 5-year return | -68.22% | -7.94% |
| EPS (TTM) | $-0.39 | $-0.57 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $6.88 | $6.30 |
| 52-week low | $0.829 | $1.58 |
| Distance from 52-week high | -85.41% | -72.70% |
| Analyst consensus | buy | strong_buy |
| Avg. price target upside | +442.83% | +481.40% |
| Average volume | 4.06M | 572.85K |
| Shares outstanding | 180.09M | 107.52M |
| Employees | 39 | 9 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- NGEN has outperformed CMPX by 27.6 percentage points over the past year.
About Compass Therapeutics
CMPX stock →Compass Therapeutics, Inc., a clinical-stage oncology-focused biopharmaceutical company, develops antibody-based therapeutics for the treatment of various human diseases in the United States. The company's lead product candidate, tovecimig, is a bispecific antibody that targets delta-like ligand 4 (DLL4) and vascular endothelial growth factor A (VEGF-A), which are critical to angiogenesis and tumor vascularization.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 39 employees
About NervGen Pharma
NGEN stock →NervGen Pharma Corp., a biotechnology company, engages in the discovery, development, and commercialization of pharmaceutical treatments to promote nervous system repair in settings of neurotrauma and neurologic disease. The company's lead product candidate is NVG-291 that is in Phase 1b/2a clinical trial for the treatment of spinal cord injuries (SCI), stroke, multiple sclerosis, and Alzheimer's disease; and NVG-300, which is in a preclinical model of ischemic stroke, amyotrophic lateral sclerosis, and confirmatory SCI study.
Health Care · Biotechnology: Pharmaceutical Preparations · 9 employees
CMPX vs NGEN FAQ
Which is bigger, Compass Therapeutics or NervGen Pharma?
NervGen Pharma (NGEN) is larger, with a market capitalization of $184.94M compared with $180.81M for Compass Therapeutics (CMPX).
Which stock has performed better over the past year, CMPX or NGEN?
NGEN returned -44.12% over the past 12 months, compared with -71.75% for CMPX (price return, excluding dividends). Past performance does not predict future results.
Are Compass Therapeutics and NervGen Pharma in the same industry?
Both are in the Health Care sector, but in different industries: Biotechnology: Biological Products (No Diagnostic Substances) for Compass Therapeutics and Biotechnology: Pharmaceutical Preparations for NervGen Pharma.